Novo Nordisk stock steadies after analyst cuts and oral Wegovy buzz
Published on 08/29/2026 at 12:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk A/S stock (DK0060534915) is moving against a crowded analyst backdrop, with Copenhagen shares quoted at DKK 298.10 on August 29, 2026 and the ADR last listed at $46.27 on August 27, 2026.
The latest catalyst is a rating split: Deutsche Bank's downgrade showed up in Danish financial coverage, while a separate note on August 28, 2026 said AlphaValue/Baader lifted its target to DKK 466 as oral Wegovy remained the main driver.
Price action stays tied to guidance
The stock's quoted DKK 298.10 level leaves it below the DKK 466 target and above the DKK 200 bearish view cited in late-August Danish coverage. That gap matters because the range from DKK 200 to DKK 466 is wide enough to keep valuation debates in the driver's seat.
On the fundamentals side, the most recent quarterly data in market coverage point to Q2 2026 revenue of $11.98 billion and EPS of $0.94, while analysts are still looking for $3.43 in full-year 2026 EPS. Revenue and earnings for the quarter were therefore both current and period-specific, while the consensus figure shows how much of the next debate still centers on profit delivery.
What the numbers say
MarketBeat's late-August alert also put Novo Nordisk's market capitalization at $206.58 billion and its P/E ratio at 11.31, with a net margin of 35.36%. Those figures frame the stock as a large, profitable drugmaker even after the recent pullback in the share price.
The current session snapshot from Yahoo Finance showed a 52-week range of $224.25 to $409.95, a volume of 2,280,734 shares, and a market cap of $1.301 trillion in intraday terms. The same page also listed a forward dividend of 11.70 and a 3.96% yield, which gives income investors another number to watch.
Wegovy stays central
Wegovy remains the representative product in the story, and the oral version has become the clearest catalyst in the latest analyst commentary. That matters because the market is now weighing a DKK 466 bull case against lower targets and a recent quoted share price close to DKK 300.
Novo Nordisk stock was last quoted at DKK 298.10 in Copenhagen on August 29, 2026. The New York-listed ADR finished at $46.27 on August 27, 2026, which keeps the U.S. trading reference in line with the European move.
More on Novo Nordisk A/S
Company: Novo Nordisk A/S
ISIN: DK0060534915
Ticker: NOVO-B.CO / NVO
Exchange: Nasdaq Copenhagen / NYSE ADR
Sector / Industry: Health Care / Drug Manufacturers - General
Index membership: OMX Copenhagen 25
Price (as of August 27, 2026, 3:59 p.m. ET): $46.27 USD
Market cap: $206.58 billion
Next earnings date: November 4, 2026
